Leverkusen, Germany, February 14, 2022 (GLOBE NEWSWIRE) — Biofrontera AG (the “Company”) (Nasdaq: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today decided that its American Depositary Shares (“ADS”) should be delisted from the Nasdaq Capital Market (“Nasdaq ”) and its reporting obligations with the Securities and Exchange Commission (“SEC”) should be discharged and terminated. The primary purpose of write-off is to reduce financial reporting complexity and administrative costs.

Biofrontera AG intends to maintain a modified ADS program on a Tier I basis, which will allow investors to continue to hold their securities in the form of ADS and to trade the ADS in the U.S. over-the-counter (OTC) market. . The ADSs will automatically switch to the new ADS program as part of the delisting and will trade under a new ticker to be designated.

Ordinary shares of Biofrontera AG will continue to trade on the Prime Standard of Deutsche Börse under the symbol B8F. ADS holders may choose to exchange their ADSs for ordinary shares listed on the Deutsche Börse.

Further details regarding the procedures will be announced at a later date. The Company expects to submit a Form 25 relating to its ADSs on the Nasdaq to the SEC on or about February 24, 2022 to initiate the delisting and expects the delisting to become effective at least ten days later.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113
WKN: 604611

Forward-Looking Statements: Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the public offering and the intended use of the proceeds of the offering.

These statements can be identified by the use of forward-looking terms such as “anticipate”, “believe”, “anticipate”, “estimate” and “intend”, among others. These forward-looking statements are based on beliefs and assumptions currently held by the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company, or industry results, to differ. materially to the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are discussed in the registration statement on Form F-1 filed with the SEC, including in the section “Risk Factors”, and in future reports filed with the SEC. In view of these risks, uncertainties and other factors, potential investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update or revise any forward-looking statement.